Drawing for CELLDEX

USPTO serial 78397614

CELLDEX

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
BENMAMAN, ALICE
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with CELLDEX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Mark Lerner

MARK LERNER SATTERLEE STEPHENS BURKE & BURKE LLP230 PARK AVE STE 1130NEW YORK, NY 10169UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005use as a housemark for Vaccines, therapeutic vaccines and therapeutic pharmaceuticals derived from monoclonal antibodies for use in the treatment of cancer, autoimmune disorders, infectious diseases and graft-verus-host diseaseACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Jun 1, 2007MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jun 1, 2007ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Sep 26, 2006EX2GSOU EXTENSION 2 GRANTED—
Sep 26, 2006EXT2SOU EXTENSION 2 FILED—
Sep 26, 2006EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 10, 2006EX1GSOU EXTENSION 1 GRANTED—
Mar 28, 2006TPEXSOU EXTENSION RECEIVED WITH TEAS PETITION—
Mar 28, 2006PETGPETITION TO REVIVE-GRANTED—
Mar 28, 2006PROATEAS PETITION TO REVIVE RECEIVED—
Mar 27, 2006EXT1SOU EXTENSION 1 FILED—
Sep 27, 2005NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Aug 17, 2005ETOPEXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED—
Jul 22, 2005ACECAMENDMENT FROM APPLICANT ENTERED—
Jul 15, 2005CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 15, 2005FAXXFAX RECEIVED—
Jul 15, 2005FAXXFAX RECEIVED—
Feb 2, 2005ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Jan 18, 2005PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 29, 2004NPUBNOTICE OF PUBLICATION—
Nov 18, 2004PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Nov 18, 2004ALIEASSIGNED TO LIE—
Nov 15, 2004PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Oct 29, 2004CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 29, 2004DOCKASSIGNED TO EXAMINER—
Apr 15, 2004NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance